Afton Scientific Capabilities Update January 2026: Fill/Finish

As an experienced aseptic CDMO, we are expanding sterile fill/finish capacity through a disciplined, phased investment strategy designed to support both near-term and long-term clinical and commercial programs. This presentation outlines our current available capacity, including RABS operations, alongside the commissioning of a new Annex 1–compliant isolator filling line and expanded QC capabilities to ensure reliable, scalable execution. Attendees will gain insight into how our forward-looking capacity planning, hands-on leadership engagement, and quality-first approach help de-risk timelines and enable durable outsourcing partnerships.